Abstract: A bending frame extends the travel of an actuator for a mechanically actuated component. The bending frame includes a plurality of bendable longitudinal struts, which are arranged about a longitudinal axis on which the travel of the actuator runs. The longitudinal struts each extend in the direction of the longitudinal axis, and an application of force enacted by the actuator long the actuation path on the longitudinal struts causes same to bend in a direction perpendicular to the longitudinal axis. Respective cross struts extend out toward the longitudinal axis from each of the longitudinal struts, wherein a first end of a respective cross strut is articulated to a respective longitudinal strut and a second end of the respective cross strut opposite to the first end is provided in order to transmit force to the component in the direction of the longitudinal axis for the purpose of actuation thereof.

Abstract: A bending frame extends the travel of an actuator for a mechanically actuated component. The bending frame includes a plurality of bendable longitudinal struts, which are arranged about a longitudinal axis on which the travel of the actuator runs. The longitudinal struts each extend in the direction of the longitudinal axis, and an application of force enacted by the actuator long the actuation path on the longitudinal struts causes same to bend in a direction perpendicular to the longitudinal axis. Respective cross struts extend out toward the longitudinal axis from each of the longitudinal struts, wherein a first end of a respective cross strut is articulated to a respective longitudinal strut and a second end of the respective cross strut opposite to the first end is provided in order to transmit force to the component in the direction of the longitudinal axis for the purpose of actuation thereof.

Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof, and compounds of formula I.

Abstract: A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): 1

Abstract: The use of KIAA0551 polypeptides and polynucleotides in the design of protocols for the treatment of neuropathies, neuropathic pain, inflammatory and chronic pain, neurodegenerative conditions such as Motor Neuron Disease, Parkinson's Disease, Alzheimer's Disease and other dementias, as well as ischaemic damage in neuronal and cardiac tissues, through disease or infectious agents, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.

Abstract: The use of KIAA0551 polypeptides and polynucleotides in the design of protocols for the treatment of neuropathies, neuropathic pain, inflammatory and chronic pain, neurodegenerative conditions such as Motor Neuron Disease, Parkinson's Disease, Alzheimer's Disease and other dementias, as well as ischaemic damage in neuronal and cardiac tissues, through disease or infectious agents, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.